

Elena Grishina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5087117/publications.pdf>

Version: 2024-02-01

63
papers

343
citations

932766

10
h-index

996533

15
g-index

66
all docs

66
docs citations

66
times ranked

373
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of CYP2C19*17 genetic polymorphisms on plasma and saliva concentrations of diazepam in patients with alcohol withdrawal syndrome. <i>Psychiatric Genetics</i> , 2022, Publish Ahead of Print, .	0.6	2
2	Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 60-67.	0.1	1
3	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 47-53.	0.3	1
4	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 41-46.	0.3	2
5	Evaluation of the association of polymorphisms of the CYP2C8 gene with the efficacy and safety of ketorolac in patients with postoperative pain syndrome. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 610-615.	0.2	0
6	Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome. <i>Hospital Pharmacy</i> , 2021, 56, 592-596.	0.4	9
7	Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder. <i>Bulletin of Siberian Medicine</i> , 2021, 19, 73-79.	0.1	0
8	Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. <i>Pharmacogenomics Journal</i> , 2021, 21, 435-439.	0.9	4
9	Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002199700.	0.5	1
10	Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin. <i>Safety and Risk of Pharmacotherapy</i> , 2021, 9, 25-33.	0.1	3
11	Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results. <i>Meditinskiy Sovet</i> , 2021, , 41-46.	0.1	1
12	Relations of CYP2C19*2 genetic polymorphisms to plasma and saliva concentrations of diazepam in patients hospitalized for alcohol withdrawal. <i>Personalized Psychiatry and Neurology</i> , 2021, 1, 84-92.	0.2	0
13	Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.5	2
14	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
15	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	1
16	Analysis of associations between pharmacodynamic genetic factors and antipsychoticsâ€™ effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 78-88.	0.2	0
17	Evaluation of the Influence of <i>CYP2C9* 2, CYP2C9*3</i> Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 570-575.	0.3	3
18	Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. <i>Journal of Psychiatric Practice</i> , 2021, 27, 372-379.	0.3	4

#	ARTICLE	IF	CITATIONS
19	Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. <i>Psychopharmacology Bulletin</i> , 2021, 51, 69-80.	0.0	0
20	Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. <i>Psychopharmacology Bulletin</i> , 2021, 51, 31-42.	0.0	0
21	MicroRNAs as Novel Biomarkers for P2Y12 Inhibitors Resistance Prediction. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1575-1582.	0.4	3
22	CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1334-1339.	0.2	0
23	Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. <i>Psychopharmacology Bulletin</i> , 2021, 51, 87-104.	0.0	0
24	Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 39-49.	0.2	0
25	CYP3A subfamily activity affects the equilibrium concentration of Phenazepam in patients with anxiety disorders and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020, 21, 449-457.	0.6	1
26	Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. <i>Pharmacogenomics</i> , 2020, 21, 677-694.	0.6	6
27	How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	9
28	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 29-37.	0.4	10
29	Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. <i>Gene</i> , 2020, 739, 144513.	1.0	12
30	Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020, 21, 111-123.	0.6	3
31	The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020, 12, 24-31.	0.2	4
32	Pharmacogenetics of the safety of phenazepam in alcohol withdrawal syndrome: haplotype and combinatorial analyses of polymorphic variants in the pharmacokinetic factor genes. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020, 12, 17-22.	0.2	1
33	Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	6
34	The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. <i>Bulletin of Siberian Medicine</i> , 2020, 18, 119-126.	0.1	0
35	New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 670-677.	0.3	3
36	Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	2

#	ARTICLE	IF	CITATIONS
37	Cognitive impairment in patients with treatment resistant schizophrenia: Associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms. <i>Neurology Psychiatry and Brain Research</i> , 2019, 33, 48-55.	2.0	8
38	Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019, 97, 781-785.	0.7	16
39	Genotyping and phenotyping CYP3A4/CYP3A5: no association with antiplatelet effect of clopidogrel. <i>Molecular Biology Reports</i> , 2019, 46, 4195-4199.	1.0	3
40	Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 329-339.	0.4	4
41	Association of CYP3A5 (6986A>G) gene polymorphism with the effectiveness of anti-inflammatory therapy in children with bronchial asthma. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2019, 64, 73-77.	0.1	0
42	The Effect of Cyp2d6 Gene Polymorphism on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders Comorbid with Alcohol. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 185-191.	0.2	0
43	The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 1-5.	0.4	8
44	Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 157-165.	0.4	14
45	Using a personalized clinical decision support system for bromdihydrochlorophenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. <i>Human Psychopharmacology</i> , 2018, 33, e2677.	0.7	17
46	Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodihydrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 187-194.	0.3	5
47	Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 43-49.	0.4	24
48	INFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 47-52.	0.3	0
49	CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 107-112.	0.4	6
50	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 113-119.	0.4	14
51	The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 109-118.	0.3	7
52	The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 127-137.	0.4	34
53	IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018, 73, 206-214.	0.2	1
54	Influence of CYP3A Activity on the Efficacy and Safety of Fluvoxamine in Patients Depressive Disorders and Comorbid Alcohol Use Disorder. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018, 73, 411-419.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 747-753.	0.3	14
56	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 129-136.	0.3	17
57	Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 209-215.	0.4	8
58	Comparison of <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2D6</i> , <i>ABCB1</i> , and <i>SLCO1B1</i> gene-polymorphism frequency in Russian and Nanai populations. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 93-99.	0.4	11
59	Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 253-259.	0.4	7
60	Do <i>CYP2C19</i> and <i>ABCB1</i> gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 243-245.	0.4	4
61	BIOCHEMICAL SUBSTANTIATION OF COMBINED THERAPY APPLICATION IN THE ACUTE PHASE OF EXPERIMENTAL HELMINTHIASIS OF ANIMALS. <i>Jurnal Infektologii</i> , 2017, 9, 32-39.	0.1	4
62	Pharmacogenetic evaluation of adverse eventsâ€™ risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms. <i>World Journal of Personalized Medicine</i> , 2017, 1, 18-26.	0.3	1
63	The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, Volume 9, 89-95.	0.4	18